ADC Therapeutics SA
ADCT NYSE
SEC CIK 1771910
Follow ADC Therapeutics
Weekly email: filings, results
Revenue, last year
$209.9M
+518.9% vs prior year
Net income
−$155.8M
+32.3% vs prior year
EPS, diluted
-
Operating cash flow
−$136.8M
+41.4% vs prior year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY22 | $209.9M | −$155.8M |
| FY21 | $33.9M | −$230M |
| FY20 | $0 | −$246.3M |
| FY19 | $2.3M | −$116.5M |
| FY18 | $1.1M | −$123.1M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY22 | 97.8% | −58.9% | −74.2% |
| FY21 | 95.9% | −771.6% | −678.2% |
| FY20 | - | - | - |
| FY19 | 100% | −5102.5% | −4977.9% |
| FY18 | - | −11047.5% | −10797.9% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY22 | −$137.4M |
| FY21 | −$236.8M |
| FY20 | −$169.5M |
| FY19 | −$121.9M |
| FY18 | −$122.3M |
| FY17 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY22 | - |
| FY21 | $0 |
| FY20 | $0 |
| FY19 | $141K |
| FY18 | $0 |
| FY17 | - |
- ADC Therapeutics
- Healthcare median
Show the numbers
| Year | ADC Therapeutics | Healthcare median |
|---|---|---|
| FY22 | −74.2% | −80.4% |
| FY21 | −678.2% | −71.9% |
| FY20 | - | −62.2% |
| FY19 | −4977.9% | −46.3% |
| FY18 | −10797.9% | −49.6% |
| FY17 | - | −45.9% |